Limits...
Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.

Liu Y, Teng Z, Wang Y, Gao P, Chen J - Med. Sci. Monit. (2015)

Bottom Line: No significant heterogeneity was observed among included studies (P>0.01, I2<50%).Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02).I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China (mainland).

ABSTRACT

Background: Osteosarcoma is the most common primary bone malignancy and has poor prognosis. Survivin has been identified as an independent prognostic factor for a majority of cancers. In the present study, we evaluated the effect of survivin expression on the clinical outcome of osteosarcoma patients.

Material and methods: Online electronic databases were searched for related articles published between 2000 and 2015. Odds ratio (OR) and risk ratio (RR) with their 95% confidence intervals (CI) were employed to calculate the significance.

Results: Overall, a total of 20 relevant studies were selected, including 1030 patients. No significant heterogeneity was observed among included studies (P>0.01, I2<50%). Survivin was expressed in 68.6% of all cases. Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02). It was associated with the grade of osteosarcoma (Enneking clinical stage, IIb-III vs. I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs. I+II: OR=2.04, 95% CI=1.16-3.61, P=0.01), metastasis, and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74-10.45, P<0.00001; OR=6.15, 95% CI=3.74-10.11, P<0.00001). No relationship was found between survivin expression and sex, age, or tumor size in patients with osteosarcoma.

Conclusions: Our results suggest that survivin can function as a new diagnostic biomarker for osteosarcoma and be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.

No MeSH data available.


Related in: MedlinePlus

Correction of survivin expression on metastasis (A) and soft tissue invasion (B) of osteosarcoma patients.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4588668&req=5

f4-medscimonit-21-2877: Correction of survivin expression on metastasis (A) and soft tissue invasion (B) of osteosarcoma patients.

Mentions: A total of 14 articles concerned sex as a factor, including 407 males and 246 females. Although the survivin expression was higher in males than in females (69.5% vs. 63.8%), we did not find a significant difference between these 2 groups in survivin expression (OR=1.26, 95% CI=0.89–1.77, P=0.19), as shown in Figure 3. All the included studies focused on age as a factor. For the various age groups presented, we could not conduct statistical analysis, but the results from each study demonstrated that there was no relationship between survivin expression and age group (P>0.05). Six articles considered tumor size, and our results did not show a significant relationship between survivin expression and tumor size of osteosarcoma (≤5 cm versus. >5 cm: OR=1.00, 95% CI=0.45–2.24, P=1.00). Eight studies including 389 patients and 7 studies including 456 patients considered metastasis and soft tissue invasion. Our results show that survivin expression was corrected with metastasis and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74–10.45, P<0.00001, Figure 4A; OR=6.15, 95% CI=3.74–10.11, P<0.00001, Figure 4B).


Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.

Liu Y, Teng Z, Wang Y, Gao P, Chen J - Med. Sci. Monit. (2015)

Correction of survivin expression on metastasis (A) and soft tissue invasion (B) of osteosarcoma patients.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4588668&req=5

f4-medscimonit-21-2877: Correction of survivin expression on metastasis (A) and soft tissue invasion (B) of osteosarcoma patients.
Mentions: A total of 14 articles concerned sex as a factor, including 407 males and 246 females. Although the survivin expression was higher in males than in females (69.5% vs. 63.8%), we did not find a significant difference between these 2 groups in survivin expression (OR=1.26, 95% CI=0.89–1.77, P=0.19), as shown in Figure 3. All the included studies focused on age as a factor. For the various age groups presented, we could not conduct statistical analysis, but the results from each study demonstrated that there was no relationship between survivin expression and age group (P>0.05). Six articles considered tumor size, and our results did not show a significant relationship between survivin expression and tumor size of osteosarcoma (≤5 cm versus. >5 cm: OR=1.00, 95% CI=0.45–2.24, P=1.00). Eight studies including 389 patients and 7 studies including 456 patients considered metastasis and soft tissue invasion. Our results show that survivin expression was corrected with metastasis and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74–10.45, P<0.00001, Figure 4A; OR=6.15, 95% CI=3.74–10.11, P<0.00001, Figure 4B).

Bottom Line: No significant heterogeneity was observed among included studies (P>0.01, I2<50%).Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02).I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China (mainland).

ABSTRACT

Background: Osteosarcoma is the most common primary bone malignancy and has poor prognosis. Survivin has been identified as an independent prognostic factor for a majority of cancers. In the present study, we evaluated the effect of survivin expression on the clinical outcome of osteosarcoma patients.

Material and methods: Online electronic databases were searched for related articles published between 2000 and 2015. Odds ratio (OR) and risk ratio (RR) with their 95% confidence intervals (CI) were employed to calculate the significance.

Results: Overall, a total of 20 relevant studies were selected, including 1030 patients. No significant heterogeneity was observed among included studies (P>0.01, I2<50%). Survivin was expressed in 68.6% of all cases. Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02). It was associated with the grade of osteosarcoma (Enneking clinical stage, IIb-III vs. I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs. I+II: OR=2.04, 95% CI=1.16-3.61, P=0.01), metastasis, and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74-10.45, P<0.00001; OR=6.15, 95% CI=3.74-10.11, P<0.00001). No relationship was found between survivin expression and sex, age, or tumor size in patients with osteosarcoma.

Conclusions: Our results suggest that survivin can function as a new diagnostic biomarker for osteosarcoma and be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.

No MeSH data available.


Related in: MedlinePlus